Autonomous Sandoz Set To Be Tighter And Leaner

Optimizing its manufacturing and supply-chain infrastructure, consolidating its regional presence into the most promising markets, and “more heavily reshaping the portfolio towards biosimilars and hard-to-make generics” are the three core elements that will take Sandoz from its current position as the world’s second-largest generics player to “a position where we can grow sustainably in the medium to long term”, Vas Narasimhan, CEO of parent group Novartis, told investors as he unveiled annual results.